Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$4.49 USD
+0.23 (5.28%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $4.48 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Voyager Therapeutics, Inc.'s return on equity, or ROE, is -37.65% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that VYGR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
VYGR 4.49 +0.23(5.28%)
Will VYGR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Other News for VYGR
VYGR forms Shooting Star Candlestick on September 17
VYGR's price rises by 0.95% on September 16, though its technical setup remains stable.
Is VYGR poised for gains? 200 Day Moving Average Support shows up after rising 0.72%
VYGR Makes Notable Cross Below Critical Moving Average
Voyager Therapeutics (VYGR): HC Wainwright & Co. Reiterates Buy Rating | VYGR Stock News